PDS Biotechnology Corp (PDSB) Stock AnalysisPDSBPDS Biotechnology Corp

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PDS Biotechnology Corp is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.2109, and the company has a negative net income of approximately $7.3 million for Q1 2026, indicating ongoing financial struggles. Additionally, the RSI is at 18.192, suggesting that the stock is heavily oversold, which may not provide a favorable entry point for long-term investors. The main risk is the company's high debt-to-equity ratio of 407.47%, which raises concerns about financial stability.